Nilotinib in Der First-Line Zugelassen

Info Onkologie
doi 10.1007/bf03362967
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Springer Science and Business Media LLC

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy